- About
- IgAN
- Events
- Resource Center
- Simulators
What interests you?+Help Us Enhance Your NephU ExperienceHelp Us Enhance Your NephU Experience
User experience form
Archives
Major Depressive Disorder In Chronic Kidney Disease
A joint virtual live event for NephU & PsychU members in Oklahoma, New Mexico, Texas, and Arkansas.
In this virtual live event, Sean George, PA-C, MHS and Laura Anguiano, PhD, discuss the high prevalence of major depressive disorder (MDD) among patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD).
Major depressive disorder affects more than 260 million people worldwide1. The reported prevalence of depression in patients with chronic kidney disease ranges from 20-65%2. This webinar provides an overview of both MDD and CKD and discusses their overlap of symptomology.
1World Health Organization. Fact Sheet on Depression. (2012) https://www.who.int/health-topics/depression#tab=tab_1
2Teles F et al. Clinics (Sao Paulo). 2014 ;69(3):198-202.*Speakers are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC).
Featured Speakers
Sean George, PA-C, MHS
Nephrology Medical Science DirectorOtsuka Pharmaceutical Development & Commercialization, Inc.*
Sean George PA-C, MHS is a Physician Assistant who currently works as a Nephrology Medical Science Director for Otsuka Pharmaceutical Commercialization and Development. He has been with Otsuka in his current role for 2 years supporting the Nephrology division. Prior to joining industry, he practiced in a private practice Nephrology clinic for 4 years managing patients with chronic kidney disease including their associated co-morbidities, anemia secondary to CKD, acute kidney injury, and end stage renal disease. In addition to his clinical work, he served on the Executive Committee for Advanced Practitioners with the National Kidney Foundation for 3 consecutive years as member-at-large, secretary, and research chair. Sean earned his Physician Assistant/Masters Health Science from the University of Oklahoma College of Medicine. He is currently licensed in the state of Oklahoma and certified with the National Commission on Certification of Physician Assistants.
Laura Anguiano, PhD
Medical Science Liaison-
Otsuka Pharmaceutical Development & Commercialization, Inc.*
Prior to joining Otsuka Laura attained a PhD in Pharmacology and Toxicology from the University of Kanas. Her doctoral work centered in the neuroscience space specifically on mechanisms of neurodegeneration and neurotoxicity. During this time Laura also served as an Adjunct Professor at Highlands Community College where she taught Human Anatomy and Physiology courses. After completion of graduate school Laura worked at a Contract Research Organization (CRO) where she managed their clinical pharmacology unit for seven years. Through these years she managed hundreds of program projects in Phases 1-2b across all therapeutic areas, i.e., oncology, neuroscience, medical devices, etc. Laura has been with Otsuka for five years now and her territories include the states of Kansas, Oklahoma and western sections of Missouri.
Location
Online via PsychU.org
NephU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI) - committed supporters of the Kidney Health Community. The information provided through NephU is intended for the educational benefit of health care professionals and others who support care for those with kidney disease and other related conditions. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing NephU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by NephU. Some of the contributors may be paid consultants of OPDC and/or OAPI.©2024 Otsuka Pharmaceutical Development & Commercialization, Inc. All rights reserved. - IgAN
